Arcus Biosciences ((RCUS)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arcus Biosciences is conducting a Phase 1/1b clinical study titled A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies. The study aims to assess the safety and tolerability of AB598 in patients with advanced cancers, a significant step in advancing cancer treatment options.
The study tests AB598, an investigational drug administered intravenously, both as a standalone treatment and in combination with other drugs like zimberelimab and FOLFOX regimen, to treat advanced cancers.
This interventional study follows a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. It involves multiple cohorts receiving AB598 every two to three weeks.
The study began on October 13, 2023, with an estimated completion date of June 26, 2025. These dates are crucial for tracking the study’s progress and potential market entry of AB598.
The study’s progress could influence Arcus Biosciences’ stock performance positively, as successful results may boost investor confidence. The competitive landscape in oncology treatments remains intense, with several companies vying for breakthroughs.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.